Skip to main navigation
Skip to main content
Skip to Footer
Global
Novartis Site Directory
Our Services
Assay Development for Intended Use
Clinical Trial Testing
Companion Diagnostics Solutions
Partnership Opportunitites
Portfolio
Our Company
Who We Are
Leadership
Join Us
Contact
Our Capabilities
Technical
Project Management
Data Management
Global Logistics
Portfolio
Lab Partnerships
Companion Diagnostics Partners
Service Inquiries
Our Experience
Navigate Team
Publications
Services Metrics
Quality
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Stories
Filter By
2015
June
Media Release
/
Jun 29, 2015
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
Read More
Media Release
/
Jun 29, 2015
Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients
Read More
Media Release
/
Jun 26, 2015
Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action
Read More
Media Release
/
Jun 18, 2015
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg
Read More
Media Release
/
Jun 18, 2015
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
Read More
Media Release
/
Jun 16, 2015
Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery
Read More
Media Release
/
Jun 13, 2015
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML
Read More
Media Release
/
Jun 13, 2015
Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control
Read More
Media Release
/
Jun 12, 2015
Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma
Read More
Media Release
/
Jun 12, 2015
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
3
of 5
Page
4
of 5
Current page
5
of 5
Page
6
of 5
Page
7
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›